Extensive production of SHV-14 beta-lactamase makes Klebsiella pneumoniae resistant to beta-lactams. The presence of omega-loop has been reported to influence the beta-lactamase activity, which is also present in SHV-14. Its omega-loop has three glutamates in nearly alternating positions 162, 164 and 167 but their concise role on the behaviour of SHV-14 is unknown. To uncover the influence of each glutamate on SHV-14, we replaced glutamates with alanine and estimated the effect of each mutation by assessing the change in beta-lactam sensitivities in the surrogate Escherichia coli cells and catalytic efficiencies for hydrolysis with the purified proteins. On expression, the clone of wild-type SHV-14 aggravated the resistance of host by 60-500 folds against penicillin and cephalosporin groups of antibiotics. However, the expression of mutated enzymes (especially E164A) substantially reduced the resistance level as compared to the wild type, and the results were in synchrony with the estimated enzymatic efficiencies of wild-type and mutated proteins. Therefore, with further support from the in silico analysis, we hypothesise that mutation at the glutamate residues in the omega-loop of SHV-14 can considerably modulate the beta-lactam sensitivity and hydrolysis, thus revealing the importance of such glutamates as the target for inhibitor design in future.
INTRODUCTION
Klebsiella pneumoniae is an opportunistic nosocomial pathogen . The production of beta-lactamase (EC 3.5.2.6) is one of the most prevalent mechanisms responsible for the resistance to beta-lactams among the clinical isolates of Enterobacteriaceae family (Philippon, Arlet and Jacoby 2002) .
Beta-lactamases have been classified into four major groups and subgroups based on function and inhibition profiles (Bush and Jacoby 2010) , whereas based on their amino acid homology Ambler classified them into four classes A, B, C and D (Livermore 1995) . Except for class B, all other classes require serine residues in their active site for catalysis and are termed as serine betalactamases. Extended-spectrum beta-lactamases (ESBLs) are often plasmid-mediated and evolve by incorporating mutations in the classical TEM and SHV beta-lactamase genes, and most are mutants of active sites that alter their affinity towards the antibiotic substrates (Jeong et al. 2004) . The penicillin-binding proteins and class A beta-lactamases including ESBLs contain a distinct loop structure called omega-loops that are non-regular structural motifs essential for stable enzyme-substrate interaction. Previous studies have reported the impact of point mutations in omega-loop residues that cause drastic variations in beta-lactamase activity due to change in active site conformations (Dutta et al. 2015; Stojanoski et al. 2015; Bansal et al. 2017) . Thus, the alterations in omega-loop residues can be considered as a hotspot in altering the substrate profile of serine beta-lactamases.
SHV beta-lactamases are broad-spectrum enzymes that have been identified in several species of enterobacteria (Chaves et al. 2001) . However, the frequent occurrence of bla SHV in K. penumoniae has led it to be considered as chromosomally borne (Leung, Shannon and French 1997; Rice et al. 2000) . The appearances of new bla SHV varieties are mostly from K. pneumoniae. Of which, bla SHV -14 is a significant variant that emerged via two substitution mutations: iso-leucine to phenylalanine at position 8 and arginine to serine at position 43 (Yuan et al. 2001) . Amino acid substitution has prompted dire changes in SHV resistance profile against penicillins and cephalosporins (Drawz et al. 2009 ). The presence of glutamate (E) residues in and around the omega-loop of serine beta-lactamases confers hydrolytic reactions by sequestering water molecules at the active site for the final deacylation reactions (Delaire et al. 1991) . However, little is known about the organisation of omega-loop of SHV-14 and its effect on its enzymatic activity. Multiple alignment analysis of amino acid sequences of SHV, CTX-M15 and TEM variants showed that glutamate positions are conserved in the omegaloop (Fig. S1 , Supporting Information). Although the CTX-M15 has similar glutamate position to SHV E162, it possesses threonine residues at the equivalent positions to E164 and E167 of SHV-14. Such changes may be responsible for the variable degree of beta-lactam hydrolysing abilities among the different betalactamases of the same class. The significance of E166 residues of TEM-1 (Leung et al. 1994; Ibuka et al. 1999; Minasov, Wang and Shoichet 2002) , which is equivalent to E162 of SHV-14 according to ABL numbering (Ambler et al. 1991) , has been reported earlier but a combined study to elucidate precise roles of three glutamate residues present on the omega-loop of SHV-14 remains elusive. Here, with the help of substitution mutagenesis, variants of SHV-14 are created to conduct the cellular level assessment, and in vitro and in silico analyses to comprehend the significance of the glutamate residues of omega-loop on the beta-lactamase functions of SHV-14.
MATERIALS AND METHODS

Bacterial strains and plasmids
The bla SHV-14 gene was isolated from the chromosomal DNA of Klebsiella pneumoniae type strain MTCC 3384 (procured from the microbial type culture collection, Institute of Microbial Technology, Chandigarh, India). Escherichia coli XLI blue (Stratagene, La Jolla, CA) strain was used for cloning experiments in pBAD18-Cam (Guzman et al. 1995) and pET28a vectors (procured from Novagen, Madison, WI). Escherichia coli BL21 (DE3) strain (procured from Stratagene, West Cedar Creek, TX) was used for protein expression. Laboratory E. coli (K-12) strain CS109 (Dutta et al. 2015) was used for cellular level evaluation of activities of SHV-14 and its mutants.
Antibiotics and reagents
All the culture media purchased from Himedia (Mumbai, India). Antibiotics and reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA). Molecular biology reagents were purchased from New England Biolabs (Ipswich, MA, USA). Isopropyl β-D-1-thiogalactopyranoside (IPTG) and dithiothreitol were purchased from Sisco Research Laboratories Pvt. Ltd, India.
Recombinant DNA methodology and mutagenesis
Genomic DNA harbouring bla SHV-14 from K. pneumoniae was extracted by the kit-based method (Nucleopore, Genetix, India); the gene was amplified by polymerase chain reaction (Eppendorf, Germany), with gene-specific primers (Table S1 ) for both full-length and soluble proteins (devoid of signal peptide and a portion of C-terminal amphipathic marker). Full-length construct of bla SHV-14 cloned and expressed in pBAD18-Cam vector (BAD SHV-14 ) under arabinose-inducible promoter to evaluate the cellular activity of mutated and wild-type genes. The soluble construct of bla SHV-14 was cloned and expressed in pET28a (+) vector (PET SHV-14 ) under lac inducible promoter. Furthermore, BAD SHV-14 and PET SHV-14 were selectively substituted with alanine at positions E162, E164 and E167 of the omega-loop (A) via the QuickChange II XL site-directed mutagenesis kit (Agilent Technologies, CA, USA) and mutations were confirmed by commercial sequencing services (MWG, Biotech, Bangalore, India). Alanine was used for substitution of glutamate because it does not eliminate the side chain beyond the β-carbon without altering the main-chain conformation nor it does impose extreme electrostatic or steric effects (Cunningham and Wells 1989) .
Antibiotic susceptibility testing
Antibiotic susceptibility was assessed by determining minimum inhibitory concentration (MIC) using the microbroth dilution method as per CLSI guidelines (Sarkar et al. 2011; Kumar et al. 2017) . Clavulanic acid (CLA) (2.5 mg L −1 ) and sulbactam (8 mg L −1 )
were used to inhibit SHV-14 activity during combination with other antibiotics (Higgins et al. 2004) .
Purification and biophysical analysis
The expressed proteins from PET with N-terminal 6X histidine tag were purified by Ni-NTA affinity chromatography using AKTA prime plus (GE healthcare, Piscataway, NJ, USA) as described earlier with some modifications. The expression levels and activity of proteins were confirmed for both soluble and full-length constructs via nitrocefin hydrolysis (Fig. S2 , Supporting Information). The molecular mass of purified proteins was determined via Matrix Assisted Laser Desorption/Ionisation-Time of Flight (MALDI-ToF) spectra using VOYAGER-DE PRO (Applied Biosystem, USA). The mass spectra were acquired in the mass range of m/z 10 000 to 40 000 Da. The analysis of protein secondary structure was done via PredicProtein server (Rost, Yachdav and Liu 2004; Dutta et al. 2015) and circular dichroism (CD) spectral analysis with JASCO J-815 CD spectrometer (JASCO International Company Limited, Tokyo, Japan) at 190-240 nm wavelengths and temperature 25 • C; data were recorded at ramp rate of 1 • C/min as described earlier (Dutta et al. 2015) .
Kinetic measurements and inhibition studies
To check the correlation between cellular level susceptibility and in vitro analysis of purified proteins, steady-state kinetics studies were carried out by following the method described earlier with certain modifications (Table S2 , Supporting Information) (Kumar et al. 2017) . The hydrolysis of various beta-lactam substrates by SHV-14 and its mutant protein (used at 0.35μM) was monitored at 25
• C in 10 mM Tris-Cl, 300 mM NaCl (pH 7.5) buffer supplemented with 1 μg mL −1 bovine serum albumin for protein stability. Kinetic constants such as K m , k cat and k cat /K m values were obtained by determining the initial rate of the reaction at different substrate concentrations based on the Michaelis-Menten equation (Dowd and Riggs 1965) . Inhibition of catalysis of SHV-14 for beta-lactams was measured similarly by pre-incubating the SHV-14 with CLA and sulbactam with varying concentrations (50-150 μM) at fixed time intervals (0-20 min) before adding the substrates (Neu and Fu 1978) .
In silico analysis
A three-dimensional tertiary structure was built by MODELLER 9v11 (Sali and Blundell 1994 ). The final model was selected based on DOPE assessment score and verified its stereochemical property by PROCHEK (Laskowski et al. 1993) server. The 3D model thus obtained was subjected to energy minimisation by YASARA server implemented on AMBER 03 force field. However, the active site groove volume, surface topology and the orientation of active site residues were determined by CASTp web server. Docking studies were carried out by Autodock4.2 to elucidate the binding interactions. Out of 20 docking conformation, the best docking poses were calculated based on the binding energy. The lowest binding energy conformations were selected to study further interactions.
RESULTS AND DISCUSSION
SHV-14 mutants displayed stable conformation post purification
Cellular expression and enzyme activity of BAD SHV-14 were confirmed via 15% SDS-PAGE and nitrocefin hydrolysis assay with Escherichia coli CS109 cell lysates after overnight induction with 0.2% arabinose (Fig. S2) . The overexpressed PET SHV-14 and its mutated proteins were purified by Ni-NTA-based metal affinity chromatography with >95% purity as observed by SDS-PAGE (Fig. 1) . Intense ionisation spectral intensities recorded via mass spectrometer confirmed the theoretical molecular mass (29.6 kDa) (Fig. 1) . Furthermore, CD spectra analysis confirmed the stable and active nature of purified enzymes. The emergence of spectra minima between 205 and 225 nm confirmed the dominance of alpha helix over beta-sheets (Fig. S3 , Supporting Information) for each protein sample. Moreover, the secondary structure data comparison derived from CD spectral analysis in combination with in silico analysis by PredictProtein server confirmed the abundance of turns followed by alpha-helix and the beta-sheets (Table 1 ). The same result was observed with mutated proteins, asserting no anomaly in protein secondary structure occurred due to point mutation.
Cells expressing mutated SHV-14 showed enhanced sensitivity to beta-lactams
Overall, three substitution mutations were targeted at the glutamate 162, 164 and 167 present on the omega-loop of SHV-14 to evaluate the individual role of mutated residue on antibiotic resistance. Cells expressing bla SHV-14 revealed very high resistance profile with elevated MIC values between 60 and 500 mg L −1 for all the beta-lactams selected (except carbapenems) as compared to control (CS109) without bla SHV-14 (Table 2a) . Interestingly, the cells expressing the mutated SHV-14 E162A and SHV-14 E164A were susceptible to the same antibiotics by >30-fold as revealed by the MIC values, confirming the active role of mutated glutamate residues in the performance of SHV-14. Moreover, a substantial reduction in MIC by 8-fold against piperacillin was observed for the cells expressing SHV-14 E164A as compared to the ones expressing SHV-14 E162A. However, the cells expressing SHV-14 E167A behaved similarly as that of the cells expressing wildtype SHV-14 for all beta-lactam antibiotics tested that asserted insignificant role of E167 in beta-lactamase activity of SHV-14. However, it had been noticed that there was a substantial 16-fold reduction of ceftazidime resistance on cellular expression of E167A mutated protein and the two other mutants as compared to SHV-14. Seeing that the values for the antibiotics, other than ceftazidime, were not clinically significant (as per CLSI guidelines) for E167A mutated enzymes as compared to E162A and E164A mutations, the SHV-14 E167A protein was not considered for further enzymatic analysis. Nevertheless, substrate docking with ceftazidime was studied for E167A mutant to comprehend the most probable reason for the decrease in resistance.
The efficacy of antibiotic-inhibitor combination was also studied to assess the residual expression of mutated genes. Interestingly, no significant alterations in susceptibility were observed for the cells expressing SHV-14 E162A and SHV-14 E164A in the presence of CLA or sulbactam used in combination with beta-lactams when compared to cellular susceptibility without any inhibitor. Nevertheless, significant differences were observed for wild-type SHV-14 with penicillinG, ampicillin and cefoperazone in combination with CLA and sulbactam. SHV-14 showed >2-fold reduced susceptibility for penicillin-CLA and >4-fold reduced susceptibility to penicillinsulbactam compared to MIC values without inhibitors. Additionally, cells with expressed SHV-14 showed >2-fold reduction for ampicillin-sulbactam and >8-fold reduction in susceptibility to ampicillin-CLA. Furthermore, substantial differences in antibiotic susceptibility were observed for cefoperazone with sulbactam and CLA inhibitors than the susceptibility without the inhibitors for the same antibiotic. SHV-14 showed >8-fold decreased susceptibility to cefoperazone-CLA and >16-fold reduction to cefoperazone-sulbactam. However, no significant change in susceptibility was observed for amoxicillin in combination with either inhibitor. Also, the cells expressing SHV-14 and its mutants appeared susceptible to carbapenems asserting a sensitive nature of CS109 E. coli cells harbouring SHV-14 for both imipenem and meropenem used in the study. Moreover, K m values of both mutated enzymes were increased by >10-fold whereas enzyme efficiency was reduced by >100-fold for ampicillin as compared to the wild-type enzyme. Similarly, a >100-fold reduction in turnover number and catalytic efficiency of mutated proteins were also observed for all beta-lactam substrates (except nitrocefin) as compared to SHV-14. Interestingly, the catalytic efficiency (k cat /K m ratio) of SHV-14 E164A was lesser than that of SHV-14 E162A that necessitates certain mechanistic analysis for the obtained behaviour to comprehend the reasons for such differences in kinetic parameters of two mutants.
Mutations in SHV-14 have made the beta-lactamase inhibitors more efficient
To check the inhibition of beta-lactam hydrolytic efficiency of SHV-14 in the presence of beta-lactamase inhibitors (sulbactam and CLA), the reactions with ampicillin and amoxicillin were carried out in the presence of different concentrations of inhibitors with varying pre-incubation time. The pre-incubation time with the inhibitors (CLA and sulbactam) is important for SHV-14 as the hydrolytic efficiency of SHV-14 was decreased with an increase in pre-incubation time and concentration of inhibitors. The presence of 150 μM sulbactam with 20-min preincubation time reduced the hydrolysis of both ampicillin and amoxicillin substrates significantly than that of CLA (Fig. 2) . Furthermore, the hydrolysing ability of both the mutated proteins (SHV-14 E162A and SHV-14 E164A) was abolished (undetected) upon combining penicillins with CLA (50 μM) or sulbactam (50 μM) (data not shown). The result indicates that mutations in SHV-14 have made the inhibitors more effective than when the inhibitors are used against wild-type SHV-14. Furthermore, to check whether the mutations had influenced the SHV-14 behaviour towards ampicillin in the presence of beta-lactamase inhibitors (CLA and Sulbactam), IC 50 values of the combinations were determined for the CS109 cells expressing SHV-14 and its mutants (Table 2b ). CS109 cells harbouring SHV-14 E167A were slightly susceptible to ampicillin/CLA and ampicillin/sulbactam combination as compared to the cells expressing SHV-14. On the other hand, the cells carrying SHV-14 E162A and SHV-14 E164A showed significant reduction in IC 50
values than the cells with SHV-14, e.g. >4-fold for ampicillin/CLA whereas for ampicillin/sulbactam combinations the IC 50 values were reduced by 50-fold and 133-fold, respectively. In short, the results indicate that E162A and E164A mutations are indeed effective even in the presence of beta-lactamase inhibitors.
The mutations have altered the active site configuration of SHV-14
To further elucidate the possible mechanism for increased susceptibility of SHV-14 mutants at the cellular level and reduced enzyme activity at in vitro level, in silico-based structure-function relationships are analysed by generating the 3D model and studying the molecular level interaction of antibiotic substrates ampicillin, piperacillin and cephalothin at the enzyme active sites via docking. The docking studies with beta-lactam substrates display significant changes in enzyme-substrate interactions. However, the overall 3D structure of the mutated proteins remained similar to the native SHV-14. The root mean square deviation (RMSD) between alpha-carbon of SHV-14 and SHV-14 E162A was 0.5Å, whereas the RMSD is 0.8Å between SHV-14 and SHV-14 E164A inferring a reliable docking result. The active site groove of serine beta-lactamases is composed of three signature motifs: SXXK, SXN and KTG (Bradford 2001) . Interestingly, the active site groove volumes of both the mutated proteins are decreased significantly [for E162A -653.9Å 3 and for E162A-(533.6Å
3 )] from that of wild-type SHV-14 (1410.7Å 3 ) indicating 2.1-fold to 2.6-fold reduction, respectively. Furthermore, the hydrogen bond length between active site residue Ser126O-γ (equivalent to Ser130 as per ABL numbering) of wild SHV-14 and ampicillin (3'O) is 2.87Å, whereas the same bond length was increased to 7.25Å and 10.59Å for E162A and E164A mutated proteins, respectively, and thus disallowing the probability of hydrogen bond formation (Fig. 3IA-C) . Also, another active site residue Asn166O-δ of SHV-14 (equivalent to Asn170 according to ABL numbering) interacts with ampicillin (via electrostatic interaction) at two positions (3'OH and N4) at the distance of 3.11Å and 3.64Å; however, the distance between the same residues is increased to 9.8Å and 8.62Å for SHV-14 E162A and a drastic 13.92Å and 17.03Å for SHV-14 E164A mutated proteins that might prohibit the crucial electrostatic interactions to carry out the hydrolytic process. Similarly, active site residue Ser66O-γ of SHV-14 (equivalent to Ser70 of ABL numbering) possibly interacts with ampicillin (3'C) at a distance of 2.61Å via moderate hydrogen bond that drastically is increased to 8.26Å and 10.59Å for E162A and E164A mutations restricting any possible hydrogen bond interaction. Moreover, active site residue Ser66N of SHV-14 interacts with piperacillin (O-8) carbonyl oxygen ( Fig. 3 .IIA-C) at a distance of 3.25Å via electrostatic interaction that is increased to 4.91Å for SHV14 E162A and 16.10Å for SHV-14 E164A, which has nullified the possibility of any interactions for catalysis. Similarly, Ser126O-γ of SHV-14 interacts with piperacillin (2'CH 3 ) at the distance of 2.5Å via strong hydrogen bond, whereas the same residue distance increased to 9.13Å for SHV-14 E162A and 18.57Å for SHV-14 E164A due to which no hydrogen bond formation is possibly feasible during the catalytic process. Also, the Asn166O-δ of SHV-14 interacts with piperacillin (3'OH) at a distance of 3.48Å via electrostatic interaction whereas the distance of the same interacting residues is increased to 12.25Å for SH-14 E162A and 21.11Å for SHV-14 E164A mutated proteins. Docking analysis with cephalothin, a first-generation cephalosporin, also shows the significant deviations from that of SHV-14 ( Fig. 3 .IIIA-C). The distance between the SHV-14 active site Ser66O-γ residue and cephalothin (3'OH) appears in strong H-bond region with 2.23Å distance, whereas the same interacting residues distance is increased to 6.4Å for SHV-14 E162A and a radical change in distance to 16.57Å for SHV-14 E164A mutated proteins. Thus, such aberrations possibly eliminate the significant molecular interaction to catalyse the hydrolysis of cephalothin. Also, a weak electrostatic interaction between active site residue Ser126O-γ and cephalothin occurs at two sites (at carbonyl oxygen and N of beta-lactam ring) at the distance of 3.83Å and 3.02Å, whereas the same interacting distance is increased to 6.67Å and 6.09Å in SHV-14 E162A, and drastically affecting SHV-14 E164A mutated proteins by increasing the distance to 19.96Å and 17.46Å, respectively. Furthermore, the active site residue Asn166O-δ of SHV-14 interacts via electrostatic interaction with cephalothin (3'OH) at the distance of 4.06Å which is increased to 5.95Å for SHV-14 E162A and 20.86Å for SHV-14 E164A, respectively, which in turn possibly rejects any possibility of even a weak interaction.
Although SHV-14 E167A behaves nearly same as SHV-14 when expressed in the CS109, a 16-fold reduction in cellular resistance against ceftazidime is identified for SHV-14 E167A expression. The docking analysis suggested a significant increase in molecular distance between the active site residues of the E167A mutated enzyme when complexed with ceftazidime (Fig. S4 , Supporting Information) that possibly restricts the possible catalytic interactions. The molecular distance between the active site residue Ser66N of SHV-14 and carbonyl oxygen (O-8) of ceftazidime is increased to 10.10Å in SHV-14 E167A from 3.01Å . Also, the distance between active site residue Ser126O-γ and ceftazidime (R-CH 3 ) of SHV-14 is increased to 10.94Å in SHV-14 E167A from 2.51Å. Similarly, the distance between active site Asn166O-δ of SHV-14 and ceftazidime (3'OH) is 2.70Å that has been changed to 17.30Å for SHV-14 E167A. Therefore, we speculate that the increase in the molecular distance of interaction between the active-site residues of SHV-14 E167A is possibly the reason behind its sensitisation against ceftazidime that might have been possible by inhibiting the possible interactions for catalysis. However, such sensitive behaviour of SHV-14 E167A mutant is only limited to ceftazidime as the docking analysis with cefoperazone does not show change in the bond distances of SHV-14 and SHV-14 E167A (Fig. S4 and Table S3 , Supporting Information).
Therefore, we speculate that the overall molecular interaction between the active site of SHV-14 and beta-lactam substrates is substantially compromised due to the point mutations that in turn impede the catalytic efficiency and cellular level activity of SHV-14. Moreover, E164A mutation hampers the effectiveness of the enzyme in a more profound way than that of E162A mutation as revealed by in silico analysis. It is also an important observation that not all the glutamate residues present in the omega-loop of serine beta-lactamases contribute to hydrolytic efficiency equally. Hence, the residue like E164 at the omega-loop can be targeted to design inhibitors against serinebeta-lactamases as these residues show conserve nature among other class A beta-lactamases.
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